0000000000404316

AUTHOR

Elisabeth Aberer

showing 3 related works from this author

S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academ…

2016

Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed specifically for patients with this disease entity, and topical and systemic drugs are mostly used 'off-label'. The aim of the present guideline was to achieve a broad consensus on treatment strategies for patients with CLE by a European subcommittee, guided by the European Dermatology Forum (EDF) and supported by the European Academy of Dermatology and Venereology (EADV). In total, 16 European participants were included in this project and agreed on all recommendations. Topical corticosteroids remain the mainstay of trea…

Systemic diseasemedicine.medical_specialtyVenereologyConsensusCalcineurin InhibitorsDermatologyDapsone030207 dermatology & venereal diseases03 medical and health sciencesAntimalarialsRetinoids0302 clinical medicineAdrenal Cortex HormonesmedicineLupus Erythematosus CutaneousHumans610 Medicine & healthlupus erythematous cuteneous guidelines treatmentLenalidomideLenalidomide030203 arthritis & rheumatologyBiological ProductsLupus erythematosusbusiness.industryfungiGuidelineMycophenolic Acidmedicine.diseaseDermatologyThalidomideClinical trialThalidomideInfectious DiseasesMethotrexatePractice Guidelines as TopicbusinessDapsoneImmunosuppressive Agentsmedicine.drug
researchProduct

Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCL…

2012

In this prospective, cross-sectional, multicenter study, we assessed clinical and laboratory characteristics from patients with cutaneous lupus erythematosus (CLE) using the Core Set Questionnaire of the European Society of Cutaneous Lupus Erythematosus (EUSCLE). 1002 (768 females, 234 males) patients with different subtypes of CLE, such as acute CLE (ACLE, 304 patients), subacute CLE (SCLE, 236 patients), chronic CLE (CCLE, 397 patients), and intermittent CLE (ICLE, 65 patients), from 13 European countries were collected and statistically analyzed by an SPSS database. The main outcome measures included gender, age at onset of disease, LE-specific and LE-nonspecific skin lesions, photosensi…

AdultMalemedicine.medical_specialtyPathologyDatabases FactualAnti-nuclear antibodyCross-sectional studyImmunologyDiseaseDiagnosis Differential030207 dermatology & venereal diseases03 medical and health sciencesSex Factors0302 clinical medicineSurveys and QuestionnairesInternal medicineLupus Erythematosus CutaneousmedicineHumansImmunology and AllergyProspective StudiesAge of OnsetGeography MedicalProspective cohort studyAgedSkin030203 arthritis & rheumatologyAutoimmune diseaseLupus erythematosusbusiness.industryfungiAge FactorsMiddle Agedmedicine.diseaseDermatologyRheumatology3. Good healthEuropeCross-Sectional StudiesFemaleAge of onsetbusinessAutoimmunity Reviews
researchProduct

Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial

2017

Summary Background Lyme borreliosis develops in 1–5% of individuals bitten by ticks, but with a diagnostic gap affecting up to 30% of patients, a broadly applicable pharmacological prevention strategy is needed. Topical azithromycin effectively eradicated Borrelia burgdorferi sensu lato from the skin in preclinical studies. We assessed its efficacy in human beings. Methods In this randomised, double-blind, placebo-controlled, multicentre trial done in 28 study sites in Germany and Austria, adults were equally assigned to receive topical 10% azithromycin or placebo twice daily for 3 consecutive days, within 72 h of a tick bite being confirmed. Randomisation numbers, which were stratified by …

AdultMale0301 basic medicinemedicine.medical_specialty030106 microbiologyPopulationAzithromycinAzithromycinPlacebolaw.invention03 medical and health sciencesTicksDouble-Blind MethodRandomized controlled triallawGermanyInternal medicinemedicineClinical endpointAnimalsHumansTreatment FailureSeroconversioneducationLyme Diseaseeducation.field_of_studybusiness.industryAntibiotic ProphylaxisMiddle Agedbacterial infections and mycosesAnti-Bacterial AgentsSurgeryClinical trialInfectious DiseasesBorrelia burgdorferiErythema migransFemalebusinessmedicine.drugThe Lancet Infectious Diseases
researchProduct